James Nugent1, Abinet Aklilu2,3, Yu Yamamoto2, Michael Simonov2, Fan Li4, Aditya Biswas2, Lama Ghazi2, Jason Greenberg1,2, Sherry Mansour2,3, Dennis Moledina2,3, F Perry Wilson2,3. 1. Section of Nephrology, Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut. 2. Clinical and Translational Research Accelerator, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut. 3. Section of Nephrology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut. 4. Department of Biostatistics, Yale University School of Public Health, New Haven, Connecticut.
Abstract
Importance: Acute kidney injury (AKI) occurs in up to half of patients hospitalized with coronavirus disease 2019 (COVID-19). The longitudinal effects of COVID-19-associated AKI on kidney function remain unknown. Objective: To compare the rate of change in estimated glomerular filtration rate (eGFR) after hospital discharge between patients with and without COVID-19 who experienced in-hospital AKI. Design, Setting, and Participants: A retrospective cohort study was conducted at 5 hospitals in Connecticut and Rhode Island from March 10 to August 31, 2020. Patients who were tested for COVID-19 and developed AKI were screened, and those who survived past discharge, did not require dialysis within 3 days of discharge, and had at least 1 outpatient creatinine level measurement following discharge were included. Exposures: Diagnosis of COVID-19. Main Outcomes and Measures: Mixed-effects models were used to assess the association between COVID-19-associated AKI and eGFR slope after discharge. The secondary outcome was the time to AKI recovery for the subgroup of patients whose kidney function had not returned to the baseline level by discharge. Results: A total of 182 patients with COVID-19-associated AKI and 1430 patients with AKI not associated with COVID-19 were included. The population included 813 women (50.4%); median age was 69.7 years (interquartile range, 58.9-78.9 years). Patients with COVID-19-associated AKI were more likely to be Black (73 [40.1%] vs 225 [15.7%]) or Hispanic (40 [22%] vs 126 [8.8%]) and had fewer comorbidities than those without COVID-19 but similar rates of preexisting chronic kidney disease and hypertension. Patients with COVID-19-associated AKI had a greater decrease in eGFR in the unadjusted model (-11.3; 95% CI, -22.1 to -0.4 mL/min/1.73 m2/y; P = .04) and after adjusting for baseline comorbidities (-12.4; 95% CI, -23.7 to -1.2 mL/min/1.73 m2/y; P = .03). In the fully adjusted model controlling for comorbidities, peak creatinine level, and in-hospital dialysis requirement, the eGFR slope difference persisted (-14.0; 95% CI, -25.1 to -2.9 mL/min/1.73 m2/y; P = .01). In the subgroup of patients who had not achieved AKI recovery by discharge (n = 319), COVID-19-associated AKI was associated with decreased kidney recovery during outpatient follow-up (adjusted hazard ratio, 0.57; 95% CI, 0.35-0.92). Conclusions and Relevance: In this cohort study of US patients who experienced in-hospital AKI, COVID-19-associated AKI was associated with a greater rate of eGFR decrease after discharge compared with AKI in patients without COVID-19, independent of underlying comorbidities or AKI severity. This eGFR trajectory may reinforce the importance of monitoring kidney function after AKI and studying interventions to limit kidney disease after COVID-19-associated AKI.
Importance: Acute kidney injury (AKI) occurs in up to half of patients hospitalized with coronavirus disease 2019 (COVID-19). The longitudinal effects of COVID-19-associated AKI on kidney function remain unknown. Objective: To compare the rate of change in estimated glomerular filtration rate (eGFR) after hospital discharge between patients with and without COVID-19 who experienced in-hospital AKI. Design, Setting, and Participants: A retrospective cohort study was conducted at 5 hospitals in Connecticut and Rhode Island from March 10 to August 31, 2020. Patients who were tested for COVID-19 and developed AKI were screened, and those who survived past discharge, did not require dialysis within 3 days of discharge, and had at least 1 outpatient creatinine level measurement following discharge were included. Exposures: Diagnosis of COVID-19. Main Outcomes and Measures: Mixed-effects models were used to assess the association between COVID-19-associated AKI and eGFR slope after discharge. The secondary outcome was the time to AKI recovery for the subgroup of patients whose kidney function had not returned to the baseline level by discharge. Results: A total of 182 patients with COVID-19-associated AKI and 1430 patients with AKI not associated with COVID-19 were included. The population included 813 women (50.4%); median age was 69.7 years (interquartile range, 58.9-78.9 years). Patients with COVID-19-associated AKI were more likely to be Black (73 [40.1%] vs 225 [15.7%]) or Hispanic (40 [22%] vs 126 [8.8%]) and had fewer comorbidities than those without COVID-19 but similar rates of preexisting chronic kidney disease and hypertension. Patients with COVID-19-associated AKI had a greater decrease in eGFR in the unadjusted model (-11.3; 95% CI, -22.1 to -0.4 mL/min/1.73 m2/y; P = .04) and after adjusting for baseline comorbidities (-12.4; 95% CI, -23.7 to -1.2 mL/min/1.73 m2/y; P = .03). In the fully adjusted model controlling for comorbidities, peak creatinine level, and in-hospital dialysis requirement, the eGFR slope difference persisted (-14.0; 95% CI, -25.1 to -2.9 mL/min/1.73 m2/y; P = .01). In the subgroup of patients who had not achieved AKI recovery by discharge (n = 319), COVID-19-associated AKI was associated with decreased kidney recovery during outpatient follow-up (adjusted hazard ratio, 0.57; 95% CI, 0.35-0.92). Conclusions and Relevance: In this cohort study of US patients who experienced in-hospital AKI, COVID-19-associated AKI was associated with a greater rate of eGFR decrease after discharge compared with AKI in patients without COVID-19, independent of underlying comorbidities or AKI severity. This eGFR trajectory may reinforce the importance of monitoring kidney function after AKI and studying interventions to limit kidney disease after COVID-19-associated AKI.
Authors: Safiya Richardson; Jamie S Hirsch; Mangala Narasimhan; James M Crawford; Thomas McGinn; Karina W Davidson; Douglas P Barnaby; Lance B Becker; John D Chelico; Stuart L Cohen; Jennifer Cookingham; Kevin Coppa; Michael A Diefenbach; Andrew J Dominello; Joan Duer-Hefele; Louise Falzon; Jordan Gitlin; Negin Hajizadeh; Tiffany G Harvin; David A Hirschwerk; Eun Ji Kim; Zachary M Kozel; Lyndonna M Marrast; Jazmin N Mogavero; Gabrielle A Osorio; Michael Qiu; Theodoros P Zanos Journal: JAMA Date: 2020-05-26 Impact factor: 56.272
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Karuna M Das; Edward Y Lee; Rajvir Singh; Mushira A Enani; Khalid Al Dossari; Klaus Van Gorkom; Sven G Larsson; Ruth D Langer Journal: Indian J Radiol Imaging Date: 2017 Jul-Sep
Authors: Mitra K Nadim; Lui G Forni; Ravindra L Mehta; Michael J Connor; Kathleen D Liu; Marlies Ostermann; Thomas Rimmelé; Alexander Zarbock; Samira Bell; Azra Bihorac; Vincenzo Cantaluppi; Eric Hoste; Faeq Husain-Syed; Michael J Germain; Stuart L Goldstein; Shruti Gupta; Michael Joannidis; Kianoush Kashani; Jay L Koyner; Matthieu Legrand; Nuttha Lumlertgul; Sumit Mohan; Neesh Pannu; Zhiyong Peng; Xose L Perez-Fernandez; Peter Pickkers; John Prowle; Thiago Reis; Nattachai Srisawat; Ashita Tolwani; Anitha Vijayan; Gianluca Villa; Li Yang; Claudio Ronco; John A Kellum Journal: Nat Rev Nephrol Date: 2020-10-15 Impact factor: 28.314
Authors: Kianoush Kashani; Mitchell Howard Rosner; Michael Haase; Andrew J P Lewington; Donal J O'Donoghue; F Perry Wilson; Mitra K Nadim; Samuel A Silver; Alexander Zarbock; Marlies Ostermann; Ravindra L Mehta; Sandra L Kane-Gill; Xiaoqiang Ding; Peter Pickkers; Azra Bihorac; Edward D Siew; Erin F Barreto; Etienne Macedo; John A Kellum; Paul M Palevsky; Ashita Jiwat Tolwani; Claudio Ronco; Luis A Juncos; Oleksa G Rewa; Sean M Bagshaw; Theresa Ann Mottes; Jay L Koyner; Kathleen D Liu; Lui G Forni; Michael Heung; Vin-Cent Wu Journal: Clin J Am Soc Nephrol Date: 2019-05-17 Impact factor: 8.237
Authors: Yuvaram N V Reddy; Rochelle P Walensky; Mallika L Mendu; Nathaniel Green; Krishna P Reddy Journal: Am J Kidney Dis Date: 2020-07-28 Impact factor: 8.860
Authors: Jamie S Hirsch; Jia H Ng; Daniel W Ross; Purva Sharma; Hitesh H Shah; Richard L Barnett; Azzour D Hazzan; Steven Fishbane; Kenar D Jhaveri Journal: Kidney Int Date: 2020-05-16 Impact factor: 10.612
Authors: Meryl Waldman; Maria Jose Soler; Clara García-Carro; Liz Lightstone; Tabitha Turner-Stokes; Megan Griffith; Joan Torras; Laura Martinez Valenzuela; Oriol Bestard; Colin Geddes; Oliver Flossmann; Kelly L Budge; Chiara Cantarelli; Enrico Fiaccadori; Marco Delsante; Enrique Morales; Eduardo Gutierrez; Jose A Niño-Cruz; Armando J Martinez-Rueda; Giorgia Comai; Claudia Bini; Gaetano La Manna; Maria F Slon; Joaquin Manrique; Alejandro Avello; Raul Fernandez-Prado; Alberto Ortiz; Smaragdi Marinaki; Carmen Rita Martin Varas; Cristina Rabasco Ruiz; Milagros Sierra-Carpio; Rebeca García-Agudo; Gema Fernández Juárez; Alexander J Hamilton; Annette Bruchfeld; Constantina Chrysochou; Lilian Howard; Smeeta Sinha; Tim Leach; Irene Agraz Pamplona; Umberto Maggiore; Paolo Cravedi Journal: Kidney360 Date: 2021-12-03
Authors: Anitha Vijayan; Emaad M Abdel-Rahman; Kathleen D Liu; Stuart L Goldstein; Anupam Agarwal; Mark D Okusa; Jorge Cerda Journal: Clin J Am Soc Nephrol Date: 2021-08-30 Impact factor: 10.614
Authors: James B Wetmore; Kirsten L Johansen; Jiannong Liu; Yi Peng; David T Gilbertson; Eric D Weinhandl Journal: J Am Soc Nephrol Date: 2021-09-17 Impact factor: 14.978